These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15700907)

  • 1. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications.
    Wilson J; Axelsen K; Tang S
    Am J Manag Care; 2005 Jan; 11 Spec No():SP27-34. PubMed ID: 15700907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid.
    Murawski MM; Abdelgawad T
    Am J Manag Care; 2005 Jan; 11 Spec No():SP35-42. PubMed ID: 15700908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Medicaid preferred drug lists on therapeutic adherence.
    Ridley DB; Axelsen KJ
    Pharmacoeconomics; 2006; 24 Suppl 3():65-78. PubMed ID: 17266389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of medicaid access restrictions on statin utilisation for patients treated by physicians practising in poor and minority neighbourhoods.
    Headen AE; Masia NA; Axelsen KJ
    Pharmacoeconomics; 2006; 24 Suppl 3():41-53. PubMed ID: 17266387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the potential link between Medicaid access restrictions, physician location, and health disparities.
    Headen A; Masia N
    Am J Manag Care; 2005 Jan; 11 Spec No():SP21-6. PubMed ID: 15700906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment.
    Dickson M; Plauschinat CA
    Ethn Dis; 2008; 18(2):204-9. PubMed ID: 18507275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of monthly prescription cap on medication persistence among patients with hypertension, hyperlipidemia, or diabetes.
    Wang CC; Wei D; Farley JF
    J Manag Care Pharm; 2013 Apr; 19(3):258-68. PubMed ID: 23537460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana.
    Virabhak S; Shinogle JA
    Am J Manag Care; 2005 Jan; 11 Spec No():SP14-20. PubMed ID: 15700905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
    Dickson M; Plauschinat CA
    Am J Cardiovasc Drugs; 2008; 8(1):45-50. PubMed ID: 18303937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?
    Ketcham JD; Epstein AJ
    Pharmacoeconomics; 2006; 24 Suppl 3():27-40. PubMed ID: 17266386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of patient comorbidities on filling of antihypertensive prescriptions.
    Lagu T; Weiner MG; Eachus S; Tang SS; Schwartz JS; Turner BJ
    Am J Manag Care; 2009 Jan; 15(1):24-30. PubMed ID: 19146361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicaid preferred drug lists' costs to physicians.
    Ketcham JD; Epstein AJ
    Med Care; 2008 Jan; 46(1):9-16. PubMed ID: 18162850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.
    Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS
    Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of controlled hypertension in indigent, inner-city hypertensive patients.
    Ahluwalia JS; McNagny SE; Rask KJ
    J Gen Intern Med; 1997 Jan; 12(1):7-14. PubMed ID: 9034941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care.
    Taira DA; Wong KS; Frech-Tamas F; Chung RS
    Am J Manag Care; 2006 Nov; 12(11):678-83. PubMed ID: 17090224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.
    Lichtenberg FR
    Am J Manag Care; 2005 Jan; 11 Spec No():SP7-13. PubMed ID: 15700904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SNAP Participation and Medication Adherence Among Older Black Medicaid-Insured Individuals Living With Hypertension.
    Ojinnaka CO; Arteaga I; Hodges L; Heflin C
    Am J Hypertens; 2023 Aug; 36(9):485-490. PubMed ID: 37225664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Pharmacy Sales Data to Assess Changes in Prescription- and Payment-Related Factors that Promote Adherence to Medications Commonly Used to Treat Hypertension, 2009 and 2014.
    Ritchey M; Tsipas S; Loustalot F; Wozniak G
    PLoS One; 2016; 11(7):e0159366. PubMed ID: 27428008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population.
    Baggarly SA; Kemp RJ; Wang X; Magoun AD
    Res Social Adm Pharm; 2014; 10(6):e99-e112. PubMed ID: 24731547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population.
    Shaya FT; Du D; Gbarayor CM; Frech-Tamas F; Lau H; Weir MR
    J Natl Med Assoc; 2009 Jan; 101(1):34-9. PubMed ID: 19245070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.